| Filed On | Filing |
|---|---|
| 05 Nov 2026 |
8-K: Other Events
Forward-Looking Statements Certain matters discussed in this presentation are “forward-looking statements” of Iovance Biotherapeutics, Inc. (hereinafter referred to as the “Company,” “we,” “us,” or “our”) within the meaning of the Privat... |
| 05 Nov 2026 |
8-K: Results of Operations and Financial Condition
Total Revenue Increased ~80% and U.S. Amtagvi Revenue Increased ~77% Year-over-Year, |
| 29 Oct 2026 |
8-K: Other Events
Iovance Reports Updated IOV-LUN-202 Results and Adds Precision TIL Strategy for Second-Line Metastatic Non-Small-Cell Lung Cancer (mNSCLC) |
| 05 Oct 2026 |
8-K: Other Events
1 © 2026, Iovance Biotherapeutics, Inc. © 2026, Iovance Biotherapeutics, Inc. Corporate Overview October 2026 1 |
| 29 Sep 2026 |
8-K: Other Events
New Guidance Represents an Increase of $55 Million at the Midpoint from the Prior Range of $350 to $370 Million |
| 06 Aug 2026 |
8-K: Other Events
1 © 2026, Iovance Biotherapeutics, Inc. Corporate Overview August 2026 1 |
| 06 Aug 2026 |
8-K: Results of Operations and Financial Condition
U.S. Amtagvi Revenue Reaches ~$91M and Total Revenue Increased 66% Year-over-Year |
| 02 Jul 2026 |
8-K: Other Events
1 © 2026, Iovance Biotherapeutics, Inc. © 2026, Iovance Biotherapeutics, Inc. Corporate Overview June 2026 1 |
| 10 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders; Other Events
First T cell therapy for a solid tumor cancer and first treatment option approved |
| 07 May 2026 |
8-K: Results of Operations and Financial Condition
1Q26 Total Revenue of ~$71M Delivers ~45% Year-over-Year Growth |
| 20 Mar 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
| 24 Feb 2026 |
8-K: Results of Operations and Financial Condition; Other Events
SAN CARLOS, Calif., February 24, 2026 -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies fo... |
| 09 Jan 2026 |
8-K: Other Events
1 © 2026, Iovance Biotherapeutics, Inc. © 2026, Iovance Biotherapeutics, Inc. Corporate Overview January 2026 1 |
| 06 Nov 2025 |
8-K: Results of Operations and Financial Condition
Gross Margin Increased to 43% on Improved Execution and Operational Efficiency |
| 29 Aug 2025 |
8-K: Other Events
1 © 2025, Iovance Biotherapeutics, Inc. © 2025, Iovance Biotherapeutics, Inc. Corporate Overview August 2025 1 |
| 22 Aug 2025 |
8-K: Entry into a Material Definitive Agreement
Iovance Biotherapeutics, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”),... |
| 19 Aug 2025 |
8-K: Other Events
First T cell therapy for a solid tumor cancer and first treatment option approved in Canada for advanced melanoma after anti-PD-1 and targeted therapy |
| 07 Aug 2025 |
8-K: Results of Operations and Financial Condition; Departure/Election of Directors or Officers; Compensation
FY25 Total Product Revenue Guidance of $250M-$300M Reiterated |
| 15 Jul 2025 |
8-K: Departure/Election of Directors or Officers; Compensation; Other Events
SAN CARLOS, Calif., July 15, 2025 -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for pa... |
| 03 Jul 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
Loading...